New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points
Tóm tắt
Từ khóa
Tài liệu tham khảo
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011. doi: 10.1007/s10120-011-0041-5 .
Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2010 (ver. 3). Gastric Cancer 2011. doi: 10.1007/s10120-011-0042-4 .
Kajitani T, Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg. 1981;11:127–45.
Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English edition. Tokyo: Kanehara; 1995.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer. 1998;1:10–24.
International Union Against Cancer. In: Sobin LH, Gospodarowicz, MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. New Jersey: Wiley-Blackwell; 2009.
Ahn HS, Lee HJ, Hahn S, et al. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116:5592–8.
Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 2009;6:71–94.
Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–8.
Cuschieri A, Fayers P, Fielding J, et al. Post-operative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet. 1996;347:995–9.
Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006;7:309–15.
Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.
Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.
Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol. 2010;28:1547–53.
Koizumi W, Narahara H, Hara T, et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
Boku N, Yamamoto S, Shirao K, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol. 2009;10:1063–9.
Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP–002). Gastric Cancer. 2011;14:72–80.